| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.
| Decembre 2018 | Study by our collaborator Dr Francis Mussai at University of Birmingham suggests arginine metabolism as a target for neuroblastoma therapy. At Sciomics we are proud of having contributed to this exciting study by a scioDiscover protein profiling study. The article is published in Cancer Research.
| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.
| January 2018 | A scioDiscover protein microarray study contributed to an article in Cell Reports. In this study Gerard Ruiz-Babot et al. analysed a donor specific reprogramming of cells.
Customer testimonial Leonardo Guasti, PhD (senior author):
This has undoubtedly opened new avenues in our research. We have found the Sciomics team to be extremely helpful and efficient during the whole process, from advising the best strategy to the final interpretation of results.
| January 2018 | Article on the StartUp Sciomics and our antibody microarray platform by our partner SCHOTT nexterion.
| February 2018 | Researchers at Rostock University Medical Center published an article on the role of Corneal Stromal Cells on Epithelial Cell Function during Wound Healing in the International Journal of Molecular Sciences.
> Customer Testimonial Bhavani Kowtharapu:
"I am really happy with service of Sciomics. Very friendly team and really fast service and we have the results in our hand including bioinformatics analysis within 2 weeks. Thank you Sciomics team."
| January 2018 | The multinational consortium MCDS-therapy has been granted 5.7 Million Euro by the European Commission for the development of novel therapeutic approaches in rare skeletal disorders. Sciomics' expertise with the antibody microarray technology herein serves as a valuable tool for biomarker identification and personalized treatment monitoring. > Press release
RT @DKTK_: #DKTK @DKFZ NachwuchswissenschaftlerInnen im Gespräch mit BM @AnjaKarliczek . Kinderarzt Anton Henssen: "Jetzt kommt es darauf a…
Eosinophils have antitumorigenic activity in CRC. See a new study by our collaborator Dr Reichmann and Dr… https://t.co/SPc2HTWO4D
RT @MCDS_Therapy: What is a #biomarker and why is the MCDS-Therapy team trying to find one? @sciomics, our partner focusing on this, have w…
Für eine Erweiterung unseres hoch motivierten Teams suchen wir - eine(n) BTA / CTA / Laborant(in) - eine administra… https://t.co/kMu1SQ1pWX
Hast Du bereits Erfahrungen im Bereich Marketing und möchtest unser Team als Hiwí (10h/Woche) unterstützen ? Wir fr… https://t.co/laXMTyP2EQ